Disc Medicine, Inc. (NASDAQ:IRON) Financings

Disc Medicine, Inc.

Financings

RaiseDate
Public offering of common stock
Made bigger: US$450M · US$75 a share · Jefferies +6
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), LifeSci Capital, BMO Capital Markets, H.C. Wainwright & Co.
Use of proceeds: Fund research and clinical development, support potential commercialization of bitopertin for EPP and XLP, pre-commercialization activities, working capital
Oct 21, 2026
Public offering of common stock and pre-funded warrants
Made bigger: about US$225M · US$84 a share · Jefferies +5
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), Wedbush PacGrow, H.C. Wainwright & Co.
Use of proceeds: Support potential commercialization of bitopertin for EPP and XLP, fund research and clinical development, working capital and general corporate purposes
Oct 21, 2025
Public offering of common stock and pre-funded warrants
Made bigger: about US$225.5M · US$55 a share · Jefferies +7
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Stifel (co-lead), Cantor (co-lead), BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, H.C. Wainwright & Co.
Use of proceeds: Research and clinical development of product candidates, potential commercialization of bitopertin for EPP and XLP, working capital and general corporate purposes
Jan 22, 2025

Read by 6ix AI from the company's releases